Enhancement of latent inhibition in the rat by the atypical antipsychotic agent remoxipride

Pharmacology Biochemistry and Behavior

Volumn 56, Issue 4, 1997, Pages 809-816

  Trimble, Karen M ^a   Bell, Robert ^a   King, David J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

haloperidol; latent inhibition; rat; remoxipride

Indexed keywords

DOPAMINE 2 RECEPTOR BLOCKING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; REMOXIPRIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONDITIONING; CONTROLLED STUDY; ELECTRIC SHOCK; EMOTION; INTRAPERITONEAL DRUG ADMINISTRATION; LATENT INHIBITION; LICKING; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REINFORCEMENT; SCHIZOPHRENIA;

ANIMALIA;

EID: 0030890668     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(96)00483-2     Document Type: Article

References (54)

1. Ahlenius S., Ericson E., Wijkstrom A. Stimulation of brain dopamine autoreceptors by remoxipride administration in reserpine-treated male rats. J. Pharm. Pharmacol. 45:1993;237-239.
2. Baruch I., Hemsley D. R., Gray J. A. Differential performance of acute and chronic schizophrenics in a latent inhibition task. J. Nerv. Ment. Dis. 176(10):1988;598-605.
3. 123I-IBZM single photon emission tomography (SPET) study. Psychopharmacology. 117:1995;55-61.
4. Carlsson A. Dopaminergic autoreceptors. Almgren L., Carlsson A., Engel J. Chemical tools in catecholamine research. 1975;219-225 North-Holland, Amsterdam.
5. Christison G. W., Atwater G. E., Dunn L. A., Kilts C. D. Haloperidol enhancement of latent inhibition. Relation to therapeutic action? Biol. Psychiatry. 23:1988;746-749.
6. Clark D., Hjorth S., Carlsson A. Dopamine-receptor agonists. Mechanisms underlying autoreceptor selectivity. I. Review of the evidence J. Neural Trans. 62:1985;1-52.
7. De la Casa L. G., Ruiz G., Lubow R. E. Amphetamine-produced attenuation of latent inhibition is modulated by stimulus preexposure duration. Implications for schizophrenia Biol. Psychiatry. 33:1993;707-711.
8. Dunn L. A., Atwater G. E., Kilts C. D. Effects of antipsychotic drugs on latent inhibition. Sensitivity and specificity of an animal behavioral model of clinical drug action Psychopharmacology. 112:1993;315-323.
9. Ellenbroek B. A., Cools A. R. Animal models with construct validity for schizophrenia. Behav. Pharmacol. 1:1990;469-490.
10. 2-dopamine receptor binding examined in vivo by PET. Acta Psychiatr. Scand. 82(358):1990;67-71.
11. Feldon J., Shofel A., Weiner I. Latent inhibition is unaffected by direct dopamine agonists. Pharmacol. Biochem. Behav. 38:1991;309-314.
12. Feldon J., Weiner I. Long-term attentional deficit in nonhandled males. Possible involvement of the dopaminergic system Psychopharmacology. 95:1988;231-236.
13. Feldon J., Weiner I. The latent inhibition model of schizophrenic attention disorder. Haloperidol and sulpiride enhance rats' ability to ignore irrelevant stimuli Biol. Psychiatry. 29:1991;635-646.
14. Gray J. A., Feldon J., Rawlins J. N. P., Hemsley D. R., Smith A. D. The neuropsychology of schizophrenia. Behav. Brain Sci. 14:1991;1-84.
15. Gray N. S., Hemsley D. R., Gray J. A. Abolition of latent inhibition in acute, but not chronic, schizophrenics. Neurol. Psychiatry Brain Res. 1:1992;83-89.
16. Gray N. S., Pickering A. D., Hemsley D. R., Dawling S., Gray J. A. Abolition of latent inhibition by a single 5 mg dose of d-amphetamine in man. Psychopharmacology. 107:1992;425-430.
17. Johansson C., Jackson D. M., Svensson L. The atypical antipsychotic, remoxipride, blocks phencyclidine-induced disruption of prepulse inhibition in the rat. Psychopharmacology. 116(4):1994;437-442.
18. Johansson C., Jackson D. M., Zhang J. H., Svensson L. Prepulse inhibition of acoustic startle, a measure of sensorimotor gating. Effects of antipsychotics and other agents in rats Pharmacol. Biochem. Behav. 52(4):1995;649-654.
19. Killcross A. S., Dickinson A., Robbins T. W. Effects of the neuroleptic alpha-flupenthixol on latent inhibition in aversively- and appetitively-motivated paradigms. Evidence for dopamine-reinforcer interactions Psychopharmacology. 115:1994;196-205.
20. Killcross A. S., Robbins T. W. Differential effects of intra-accumbens and systemic amphetamine on latent inhibition using an on-baseline, within-subject conditioned suppression paradigm. Psychopharmacology. 110:1993;479-489.
21. Klieser E., Strauss W. H., Lemmer W. The tolerability and efficacy of the atypical neuroleptic remoxipride compared with clozapine and haloperidol in acute schizophrenia. Acta Psychiatr. Scand. 89(380):1994;68-73.
22. Köhler C., Hall H., Magnusson O., Lewander T., Gustafsson K. Biochemical pharmacology of the atypical neuroleptic remoxipride. Acta Psychiatr. Scand. 82(358):1990;27-36.
23. Lewander T., Uppfeldt G., Köhler C., Ericson H., von Bahr C., Movin-Osswald G. Remoxipride and raclopride. Pharmacological background and clinical outcome Meltzer H. Y. Novel antipsychotic drugs. 1992;67-78 Raven Press, Ltd, New York.
24. Lewander T., Westerbergh S. E., Morrison D. Clinical profile of remoxipride-combined analysis of a comparative double-blind multicentre trial programme. Acta Psychiatr. Scand. 82(358):1990;92-98.
25. Lubow R. E. Latent inhibition. Psychol. Bull. 79:1973;398-407.
26. Lubow R. E. Latent inhibition and conditioned attention theory. 1974;Cambridge University Press, Cambridge, UK.
27. MacKintosh N. J. A theory of attention. Variations in the associability of stimuli with reinforcement Psychol. Rev. 82(4):1975;276-298.
28. MacKintosh N. J. Conditioning and associative learning. 1983;Oxford University Press, New York.
29. 2 receptors and dopamine metabolism. Relationship between biochemical and behavioural effects of substituted benzamide drugs. Neuropharmacology. 25:1986;187-197.
30. Magnusson O., Fowler C. J., Mohringe B., Wijkstrom A., Ögren S.-O. Comparison of the effects of haloperidol, remoxipride and raclopride on 'pre'- and postsynaptic dopamine receptors in the rat brain. Naunyn Schmiedebergs Arch. Pharmacol. 337:1988;379-384.
31. 2 selective receptor antagonist remoxipride on dopamine turnover in the rat brain after acute and repeated administration. Pharmacol. Toxicol. 60:1987;368-373.
32. Moran P. M., Fischer T. R., Hitchcock J. M., Moser P. C. Effects of clozapine on latent inhibition in the rat. Behav. Pharmacol. 7:1996;42-48.
33. 3 antagonist, facilitates latent inhibition in the rat. Pharmacol. Biochem. Behav. 42:1992;519-522.
34. Ögren S. O., Florvall L., Hall H., Magnusson O., Angeby-Möller K. Neuropharmacological and behavioural properties of remoxipride in the rat. Acta Psychiatr. Scand. 82(358):1990;21-26.
35. Ögren S. O., Hall H., Köhler C., Magnusson O., Lindbom L.-O., Angeby K., Florvall L. Remoxipride, a new potential antipsychotic compound with selective anti-dopaminergic actions in the rat brain. Eur. J. Pharmacol. 102:1984;459-474.
36. Ögren S. O., Lundstrom J., Nilsson L. B. Concentrations of remoxipride and its phenolic metabolites in rat brain and plasma. Relationship to extrapyramidal side effects and atypical antipsychotic profile. J. Neural Trans. 94(3):1993;199-216.
37. Olbrich R., Schanz H. The effect of the partial dopamine agonist terguride on negative symptoms in schizophrenics. Pharmaco-psychiatry. 21(6):1988;389-390.
38. Peters S. L., Joseph M. H. Haloperidol potentiation of latent inhibition in rats. Evidence for a critical role at conditioning rather than preexposure Behav. Pharmacol. 4:1993;183-186.
39. Potkin S. G., Anand R. A partial dopamine agonist, SDZ HDC-912 has antipsychotic efficacy. Biol. Psychiatry. 33(6A SS):1993;A129.
40. Ross S. B. Is the sigma opiate receptor a proadifen-sensitive subform of cytochrome P450? Pharmacol. Toxicol. 67:1990;93-94.
41. Roth R. H. CNS dopamine autoreceptors. Distribution, pharmacology and function Ann. N.Y. Acad. Sci. 430:1984;27-53.
42. Solomon P. R., Crider A., Winkelman J. W., Turi A., Kamer R. M., Kaplan L. J. Disrupted latent inhibition in the rat with chronic amphetamine or haloperidol-induced supersensitivity. Relationship to schizophrenic attention disorder Biol. Psychiatry. 16(6):1981;519-537.
43. Solomon P. R., Staton D. M. Differential effects of microinjections of d-amphetamine into the nucleus accumbens or the caudate putamen on the rat's ability to ignore an irrelevant stimulus. Biol. Psychiatry. 17(6):1982;743-756.
44. Warburton E. C., Joseph M. H., Feldon J., Weiner I., Gray J. Antagonism of amphetamine-induced disruption of latent inhibition in rats by haloperidol and ondansetron. Implications for a possible antipsychotic action of ondansetron Psychopharmacolgy. 114:1994;657-664.
45. Weiner I. Neural substrates of latent inhibition. The switching model Psychol. Bull. 108(3):1990;442-461.
46. Weiner I., Feldon J. Facilitation of latent inhibition by haloperidol in rats. Psychopharmacology. 91:1987;248-253.
47. Weiner I., Feldon J. The latent inhibition model of schizophrenic attention disorder and of antipsychotic drug action. Comment on Dunn, Atwater and Kilts (Psychopharmacol. 112:315-323; 1993) Psychopharmacology. 116:1994;379-380.
48. Weiner I., Feldon J., Katz Y. Facilitation of the expression but not the acquisition of latent inhibition by haloperidol in rats. Pharmacol. Biochem. Behav. 26:1987;241-246.
49. Weiner I., Kidron R., Tarrasch R., Arnt J., Feldon J. The effects of the new antipsychotic, sertindole on latent inhibition in rats. Behav. Pharmacol. 5(2):1994;119-124.
50. Weiner I., Lubow R. E., Feldon J. Chronic amphetamine and latent inhibition. Behav. Brain Res. 2:1981;285-286.
51. Weiner I., Lubow R. E., Feldon J. Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats. Psychopharmacology. 83:1984;194-199.
52. Weiner I., Lubow R. E., Feldon J. Disruption of latent inhibition by acute administration of low doses of amphetamine. Pharmacol. Biochem. Behav. 30:1988;871-878.
53. Weiner I., Shofel A., Feldon J. Disruption of latent inhibition by low dose of amphetamine is antagonised by haloperidol and apomorphine. J. Psychopharmacol. 4:1990;255.
54. Weiner I., Traub A., Rawlins J. N. P., Smith A. D., Feldon J. The sigma ligand BMY-14802 as a potential antipsychotic. Evidence from the latent inhibition model in rats Behav. Pharmacol. 6:1995;46-54.